Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11258217 | 0.88 | GRM4 (0.55) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL11249634 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL4100669 | 0.87 | KMT2A (0.51) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL4104318 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP2C19KMT2A | |
| SCHEMBL7760777 | 0.83 | CYP1A2 (0.65) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL11259998 | 0.82 | MAPT (0.58) | ALDH1A1KMT2AMAPTL3MBTL1MAPK1 | |
| SCHEMBL11254618 | 0.81 | IMPDH2 (0.64) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL7166437 | 0.81 | KMT2A (0.60) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL4105580 | 0.81 | NPC1 (0.58) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL1184403 | 0.80 | KMT2A (0.57) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| EP-0888141-B1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND THEIR USE FOR TREATING HYPERALGESIC CONDITIONS THEREWITH | ADOLOR CORP (US) | 2004-05-26 | — | — | EP | claimed |
| EP-1119354-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-02-12 | — | — | EP | claimed |
| JP-2002527392-A | — | — | 2002-08-27 | — | — | JP | claimed |
| US-6353004-B1 | TREATMENT OF PRUTITIC CONDITION IN VAGINA | ADOLOR COPORATION | 2002-03-05 | — | — | US | claimed |
| EP-1119354-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2001-08-01 | — | — | EP | claimed |
| EP-0888141-A4 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC CONDITIONS THEREWITH | ADOLOR CORP (US) | 2001-01-17 | — | — | EP | claimed |
| WO-2000021530-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0888141-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC CONDITIONS THEREWITH | Adolor Corporation (US) | 1999-01-07 | — | — | EP | claimed |
| US-5849762-A | Peripherally acting anti-pruritic opiates | ADOLOR CORPORATION (US) | 1998-12-15 | — | — | US | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997033634-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC CONDITIONS THEREWITH | ADOLOR CORPORATION (US) | 1997-09-18 | — | — | WO | claimed |
| US-5667773-A | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith | ADOLOR CORPORATION (US) | 1997-09-16 | — | — | US | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| US-4025652-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1977-05-24 | — | — | US | claimed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| US-4326074-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4285972-A | Method of treating scours | WILLIAM H. RORER, INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4115564-A | Treatment of diarrhea with amidinoureas | WILLIAM H. RORER, INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | SMN1; SMN2 3027/4885RAB9A 2870/4885ALDH1A1 1963/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | SMN1; SMN2 3724/4885RAB9A 1539/4885ALDH1A1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.